Background Most (70%) epithelial ovarian cancers (EOCs) are diagnosed late. Non-invasive
biomarkers that facilitate disease detection and predict outcome are needed. The …

Ovarian cancer patients are recognized with poor prognosis. This study aimed to identify
microRNAs in plasma for predicting response to treatment and outcome. We have …

MicroRNAs play critical roles in regulating tumor occurrence and drug sensitivity in ovarian
cancers. This study aimed to investigate the key members of MicroRNAs (miRNAs) involved …

The role of microRNAs (miRNAs or miRs) in the pathology of epithelial ovarian cancer
(EOC) has been extensively studied. Many miRNAs differentially expressed in EOC as …

The non-invasive diagnostic tool for early detection of endometrial cancer still limited. The
etiology of this disease is believed to be associated with disharmony hormone production …

Ovarian cancer accounts for the highest mortality among all gynecologic cancers.
Cytoreductive surgery followed by chemotherapy with a platinum-based agent (cisplatin or …

It has been almost two decades since the first link between microRNAs and cancer was
established. In the ensuing years, this abundant class of short noncoding regulatory RNAs …

Epithelial ovarian cancer (EOC) is the leading cause of mortality with regard to
gynaecological cancer. There is no effective biomarker and therefore prognosis is poor as …

Previous studies have identified microRNA (miRNA) involvement in human cancers. This
study aimed to elucidate potential clinical and biological associations of ovarian cancer …

Ovarian cancer (OC) is the second most common and the most fatal gynecologic cancer in
the United States. Over the last decade, various targeted therapeutics have been introduced …